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ABSTRACT Tyrosine aminotransferase (TAT; L-tyro-
sine:2-oxoglutarate aminotransferase, EC 2.6.1.5) gene activ-
ity is stimulated by glucocorticoids and glucagon and is re-
pressed by insulin. Expression and responsiveness to the dif-
ferent signal transduction pathways are restricted to the liver,
in which the gene is activated shortly after birth. Here we
provide a model for the basis of this tissue specificity of the
hormonal control. In the two enhancers mediating hormone
induction of TAT gene activity we find the hormone response
elements in combination with binding sites for constitutive
liver-enriched transcription factors: proteins of the hepatocyte
nuclear factor 3 family bind in the vicinity of the glucocorticoid
response element located 2.5 kb upstream of the transcription
start site, while hepatocyte nuclear factor 4 interacts with an
essential element in the cAMP-responsive enhancer at -3.6 kb.
By juxtaposing the liver-specific element and the target se-
quence of the signal transduction pathway the regulatory
properties of either enhancer can be reconstituted. Thus, the
interdependence of the respective enhancer motifs restricts the
hormonal activation of the TAT gene to the liver. The coinci-
dence of the onset ofTAT gene expression around birth with the
perinatal changes in the concentrations of glucocorticoids,
glucagon, and insulin suggests cooperation of signal transduc-
tion pathways and cell type-specific transcription factors in the
developmental activation of the TAT gene.
Gene activity is regulated in response to temporal, spatial,
and environmental cues. In the last 10 years many sequence
motifs have been discovered which are involved in deter-
mining tissue-specific and developmentally regulated gene
expression. These cis-regulatory elements interact with
trans-acting factors which influence the rate of transcription
and which often exhibit correspondingly restricted expres-
sion patterns (1, 2). Similarly, changes in gene expression in
response to external signals such as growth factors and
hormones are mediated by altering the function of specific
transcription factors. Two major types of signal transduction
pathways have been elucidated: (i) signaling molecules such
as steroid hormones influence gene activity by inducingDNA
binding of their intracellular receptors (3, 4); (ii) binding of
many growth factors or peptide hormones to specific cell-
surface receptors elicits a cascade of events mediated by
second messengers, which affect the activity of protein
kinases and phosphatases, as well as Ca2+ levels. These
changes finally result in the modification of specific tran-
scription factors, thereby changing their activities (5).
While the components of the signal transduction pathways
are mostly of ubiquitous nature, hormonal stimulation of a
particular gene is often restricted to certain cell types. We
have chosen the tyrosine aminotransferase (TAT) gene as a
model system to study the basis of this cell type-specificity of
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hormone induction and its role in developmental gene acti-
vation. The TAT gene is transcriptionally responsive to
members of both classes of signaling pathways. It is induced
by glucocorticoids and glucagon, acting via its intracellular
mediator cAMP (6-8), and is repressed by insulin (9). The
hormone-regulated expression is restricted to the parenchy-
mal cells of the liver, in which the gene is activated shortly
after birth (10, 11). We show here that in the two enhancers
at -2.5 and -3.6 kb (relative to the transcription start site)
which respond to glucocorticoids and glucagon, respectively
(12, 13), the hormone response elements synergize with
binding sites for the liver-enriched transcription factors he-
patocyte nuclear factor 3 (HNF3; refs. 14 and 15) and HNF4
(16). Therefore, the interdependence of the hormone re-
sponse elements and cell type-specific enhancer motifs seems
to be the basis of the strictly liver-specific hormonal induc-
ibility ofTAT gene expression and may provide the switch for
the developmentally timed activation of the gene.
EXPERIMENTAL PROCEDURES
Plasmid Constructions. In plasmid 3.OTK the Sal I-Kpn I
fragment from pTATCAT (12) was cloned into the polylinker
of pBLCAT2 (17), generating a construct containing TAT 5'
flanking sequences from -2950 to -351 bp in front of the
herpes simplex virus thymidine kinase (TK) promoter. Con-
structs -2.5HSTK and 2xGRETK are described elsewhere
(18). The constructs containing one or two copies of the TAT
glucocorticoid response element (GRE) in front of the TAT
promoter have been described previously as GRE-351TAT
and 2GRE-351TAT (19). In all other constructs depicted in
Fig. 4A the following oligonucleotides were cloned in the
sense orientation into the BamHI site of GRE-351TAT:
HNF3(TAT-2.5), 5'-GATCTACGCAGGACTTGTTTGT-
TCTAGTCG-3'; HNF3(TAT-11), 5'-GATCCGACGTTTC-
TCAATATTTGCTCTGGCAGATA-3'; -llmut, 5'-GATC-
CGACGTTTATACATATTTTATCTGGCAGATA-3 ';
HNF4, 5'-GATCTGCTGCTCTTTGATCTG-3'; HNF4mut,
5'-GATCTGCTGCGAGGGGATCTG-3' (the mutated base
pairs are underlined). The cAMP response element (CRE)-
HNF4 and CRE-HNF4mut constructs (Fig. 4B) are described
as plasmids BI/BIII and BI/BIII(M12) in ref. 13. The CRE-
HNF3 heterodimers were constructed correspondingly, in-
serting the HNF3 oligonucleotides (see above) instead of the
HNF4 (BIII) motif. All constructs containing oligonucleo-
tides were verified by plasmid sequencing (20).
Abbreviations: CAT, chloramphenicol acetyltransferase; CRE,
cAMP response element; GRE, glucocorticoid response element;
HNF, hepatocyte nuclear factor; TAT, tyrosine aminotransferase;
TK, thymidine kinase.
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Cell Culture and Transient Transfections. All experiments
were performed with FTO2B hepatoma and XC fibrosarcoma
("fibroblast") rat cell lines. Cell culture, transfection exper-
iments, and chloramphenicol acetyltransferase (CAT) assays
were performed as described (13). Cells were harvested 48 hr
after electroporation and hormone additions.
Gel Mobility-Shift Assays. Mobility-shift experiments were
performed as described (18). Rat liver nuclear extract was
prepared and partially purified by DEAE-Sepharose chro-
matography (21). The antisera directed against HNF3a, -/3,
and -y were generously provided by V. Prezioso and J.
Darnell (15). HNF4-specific antiserum was kindly provided
by F. Sladek and J. Darnell (16).
RESULTS
Members of the HNF3 Family of Liver-Enriched Transcrip-
tion Factors Bind to the Glucocorticoid-Inducible Enhancer of
the TAT Gene. The TAT gene is induced by glucocorticoids
exclusively in the liver, and this cell-type specificity of the
hormone response can be reproduced in transient-
transfection experiments (Fig. 1). Constructs containing TAT
5' flanking sequences, including the glucocorticoid-inducible
enhancer at -2.5 kb (12), in front of the promoter of the
herpes simplex virus TK gene, are induced >50-fold in
hepatoma cells by the addition ofthe synthetic glucocorticoid
dexamethasone. Whereas two copies of the GRE from the
TAT enhancer (2xGRETK) stimulate the TK promoter in
both hepatoma and fibroblast cells, the complete enhancer
either contained on a 250-bp fragment (-2.5HSTK) or in its
natural position at -2.5 kb (3.OTK) strongly responds to
hormone only in the hepatoma cell line. Thus, it appears that
sequences located within the glucocorticoid-inducible en-
hancer restrict its activity to the liver.
We noted a sequence motif -60 bp downstream ofthe GRE
with striking homology to an important element contained in
the constitutive liver-specific TAT enhancer located at -11
kb (Fig. 2D; ref. 22), which has recently been found to bind
liver-enriched transcription factors ofthe HNF3 family (D.N.
and G.S., unpublished work). To test whether the sequence
in the glucocorticoid-inducible enhancer also interacts with
HNF3 proteins, we performed gel mobility-shift analyses
with an oligonucleotide containing the respective sequence
motif (TAT-2.5; Fig. 2). With extracts prepared from either
hepatoma or fibroblast cells several prominent protein-DNA
complexes were observed, only one ofwhich was common to
both extracts (Fig. 2A). To define the specificity of the
protein-DNA complexes we performed competition experi-
ments with different oligonucleotides, which showed that the
sequence derived from the TAT enhancer at -2.5 kb con-
tained an HNF3 binding site (Fig. 2B): In the presence of the
HNF3 motif from the transthyretin gene (HNF3; ref. 23) or
from the TAT enhancer at -11 kb (TAT-11), the hepatoma
cell-specific protein-DNA complexes are not formed,
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FIG. 2. HNF3a, -(3, and --y bind to the glucocorticoid-inducible
enhancer at -2.5 kb. (A) Comparison of protein-DNA complex
formation with nuclear extracts prepared from hepatoma or fibro-
blast cells. Position of unbound oligonucleotide probe containing the
HNF3 site at -2.5 kb (TAT-2.5) is indicated (free). (B) Labeled
oligonucleotides containing either the TAT-2.5 sequence (lanes 1-5)
or an HNF3 binding site from the transthyretin gene (ref. 23; lanes
6 and 7) were incubated with hepatoma cell extracts in the absence
(-) or presence of 100-fold molar excess of the indicated unlabeled
oligonucleotide competitor (comp.). The HNF4 binding site is also
derived from the transthyretin gene (23). (C) Hepatoma cell extracts
were incubated with labeled HNF3 oligonucleotide TAT-2.5 in the
presence of preimmune serum [control (c) lane 1] or antiserum
directed against HNF3a (lane 2),
-,B (lane 3), or -y (lane 4). (D)
Comparison of the sequence derived from the TAT enhancer at -2.5
kb [HNF3 (TAT-2.5)] with the HNF3 consensus binding site (23) and
the HNF3 motiffrom the TAT enhancer at -11 kb [HNF3 (TAT-11)].
Homologous positions are indicated by vertical lines. Squares above
and below the sequence illustrate the HNF3-specific DNA contacts
as determined by methylation interference analyses (data not
shown).
whereas complex formation is not influenced by excess of an
HNF4 binding site (Fig. 2B, lanes 1-4). Consistent with these
results, the TAT-2.5 oligonucleotide competed for formation
of the complexes obtained with the HNF3 motif from the
transthyretin gene (Fig. 2B, lanes 6 and 7). Further, with the
help of specific antisera (kindly provided by V. Prezioso and
J. Darnell), we demonstrated that HNF3a, -/3, and
-y were
contained in the hepatoma cell-specific protein-DNA com-
plexes obtained with the sequence from the TAT enhancer at
-2.5 kb (Fig. 2C).
Thus, an HNF3 binding site is located in the vicinity of the
GRE in the glucocorticoid-inducible TAT enhancer and it
O N ¢> fold induction
bp u) LO c LO Hepatoma Fibroblast
3.0T3.OTK KCT 85.0 1.1
-2.5HSTK 116.0 3.0
GRE
2xGRETK 18.0 23.0
FIG. 1. The glucocorticoid-inducible enhancer of the TAT gene is active in hepatoma cells but not in fibroblasts. Reporter constructs
containing different parts of the TAT gene 5' flanking sequence cloned in front of the herpes simplex TK promoter driving the CAT gene were
transiently transfected into hepatoma and fibroblast cells. TAT sequences are depicted as shaded bars with the GRE (-2509 to -2495 bp; ref.
12) indicated by a black square. The table on the right gives the values for the fold induction in response to 0.3 ,uM dexamethasone from a
representative transfection experiment.
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FIG. 3. The HNF4 protein binds to the cAM
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complex. (B) Labeled oligonucleotides containini
3.6wt sequence (lanes 1-7) or the HNF4 bindi
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the indicated unlabeled oligonucleotide competi
Hepatoma cell extracts (lanes 1 and 2) or partii
extracts (lanes 3 and 4) were incubated with labele
TAT-3.6wt in the presence of 3% bovine serum alb
lanes1 and 3] or antiserum directed against HNF4(
Comparison of the sequence derived from the TAT
kb [HNF4 (TAT-3.6wt)], with the HNF4 consensu
Homologous positions are indicated by verticallin
mutated in oligonucleotides -3.6M12 and
-3.6M
(see ref. 13). The squares above and below the sequ
DNA contacts of the HNF4 protein derived from li
by methylation interference analysis (data not shc
ins HNF3a, -p, the most prominent complex (arrow). Transient-transfection
binding to this experiments with wild-type and mutated enhancer sequenceshift formed with identified a 10-bp motif in which clusters of five point
ells could not be mutations abolished enhancer activity (M12 and M13 in ref.
ar an HNF3, an 13). Competition experiments with oligonucleotides contain-2B, lanes 2-5), ing the wild-type or mutated sequences revealed that loss of
-DNA complex enhancer function correlated with the inability to form theld molar excess hepatoma cell-specific protein-DNA complexes (Fig. 3B,
showed a meth- lanes 1-4).
nguishable from Partially purified liver nuclear extracts gave rise to one
ita not shown). major protein-DNA complex, which corresponded in mobil-
-DNA complex ity and sequence specificity to the most prominent DNA-
mne family (refs. binding activity observed with hepatoma cell extracts (Fig.
blished results). 3C). Reciprocal oligonucleotide competition (Fig. 3B, lanesiMP-Responsive 5 and 9) and immunoshift experiments with HNF4-specific
,er at -3.6 kb is antiserum (a kind gift from F. Sladek and J. Darnell; Fig. 3C)
'RE and a cell clearly showed that this protein-DNA complex contained
er liver-specific HNF4. Comparison of the competition experiments and theis recognized by immunoshift analyses revealed that only one of the specific
EB/ATF family complexes was formed by HNF4 (arrow). Formation of thehe liver-specific weak protein-DNA complexes of higher mobility was af-
el mobility-shift fected by an excess of the HNF3 motif (Fig. 3B, lane 6). This
ng the cell type- observation may be related to the fact that the HNF4 and
'ig. 3A shows a HNF3 motifs from the TAT enhancers show a high degree of
tained with ex- sequence similarity, with identity in 8 of 10 positions (TNTT-
st cells. Several TGNTCT; compare Figs. 2D and 3D). However, only with a
ma cell extract, 400-fold molar excess of the respective oligonucleotides did
lane, including we observe weak cross competition (data not shown).
A comparison of the sequence from the TAT enhancer at
C ,
-3.6 kb and the published HNF4 consensus binding site (26)
reveals homology in 7 of 12 positions (Fig. 3D). The DNA
contacts determined by methylation interference analysisI CaNNF $4 (open squares in Fig. 3D) are centered in the region of
4 homology and lie within a mutation-sensitive domain of the
* * enhancer as determined in transient-transfection experi-
ments (13). The phenotypes of the neighboring clusters of
point mutations also fit to the HNF4-specific protein-DNA
contacts: the 5'-adjacent mutant, containing mutations at two
guanines whose methylation interferes with HNF4 binding,
has only -50% of wild-type activity; the3'-adjacent mutant
shows wild-type activity and its base-pair exchanges lie
1 2 3 4 outside the region of protein-DNA contacts (Mll and M14 in
ref. 13). Thus, the experiments depicted in Fig. 3 document
M13 that the essential hepatoma cell-specific motif of the cAMP-
ATCTGTATACC responsive TAT enhancer interacts with the transcriptionTAGACATATGG factor HNF4.
Binding Sites for Liver-Specific Transcription Factors Syn-
c ergize with the Hormone Response Element. Having identifiedCA binding sites for the liver-enriched transcription factors
HNF3 and HNF4 near the GRE and CRE, respectively, we
[P-responsive en- wanted to test whether the characteristics of each enhancer
INA complex for- could be reconstituted by combining the respective enhancer
toma or fibroblast motifs. Previously, a single GRE has been shown to function)e containing the proximally but not distally to the transcription start site (19).b (TAT-3.6wt) iS We therefore cloned the GRE and the HNF3 binding site in
gieic protein-DNA the promoter-distal position at -351 bp with respect to the
ng site fromthe TAT transcriptionstart site. In addition we tested the HNF3iithhepatomacell motif derived from the enhancer at -11 kb in an analogous
d molar excess of construct. As a positive control, a construct containing aitor (comp.). (C) tandem repeat of the GRE was tested, which has been shown
ally purified liver to confer inducibiity by glucocorticoid in several cell lines4d oligonucleotide (19). The constructs were transfected into rat hepatoma and
umin [control (c), fibroblast cells and their activities were measured in thelanes 2and 4). (D) presence and absence of glucocorticoid hormone (Fig. 4).
s enhancer at-(3.6 The construct containing two copies of the GRE showed a
s binding site (26). strong hormone-dependent activity in hepatoma and fibro-
13are bracketed blast cells, as expected; in contrast, both GRE-HNF3 com-
tence illustrate the binations were inducible only in the hepatoma cell line. As aiver as determined control and to rule out any effect of spacing or sequence
)wn). environment, we also tested a construct in which the HNF3
A
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FIG. 4. Synergism between hormone response elements and binding sites for liver-specific transcription factors. Oligonucleotides with the
indicated enhancer motifs (for sequences, see Experimental Procedures) were cloned at -351 bp of the TAT promoter (A) or -105 bp of the
herpes simplex virus TK promoter (B), both driving the CAT gene. Constructs were transiently transfected into hepatoma or fibroblast cells,
and the cells were split onto two plates and either mock-induced (solvent control) or induced with 0.3 ,uM dexamethasone (A) or 1 AM forskolin
(B). The constructs are depicted with the different transcription factor binding sites represented by hatched and shaded symbols. Crossed-out
symbols represent binding sites inactivated by mutation M12 (see ref. 13). The tables give the fold induction by glucocorticoid (A) or the relative
CAT activities in the absence (-) or presence (+) of forskolin, with the activity of the TK promoter construct set to 1 (B). All GRE-containing
constructs (A) show only vector-background activity in the absence of hormone. Each construct was tested at least three times in hepatoma
cells and twice in fibroblasts. Results of representative experiments are depicted. n.d., Not determined.
motif was mutated. Mutation of five nucleotides which abol-
ished protein-DNA binding in vitro (Fig. 2B, lane 5) impaired
the hormone-dependent stimulation of the TAT promoter,
indicating that the HNF3 motif synergizes with the GRE.
Thus, the regulatory properties of the TAT enhancer at -2.5
kb can be reconstituted by combining its GRE and HNF3
binding site. Likewise, the liver-specific and cAMP-
responsive activity of the TAT enhancer at -3.6 kb can be
reconstituted by juxtaposing the HNF4 motif and the CRE in
front of the heterologous TK promoter (Fig. 4B). Mutations
in the HNF4 binding site which affect DNA binding (Fig. 3B,
lane 3) reduce basal as well as cAMP-induced activities of the
corresponding construct.
To see whether the synergism between the cell type-
specific and the hormone response elements was specific to
the combinations found in the two TAT enhancers, we
constructed reporter plasmids in which the binding sites for
the two liver-enriched factors were swapped. As documented
in Fig. 4A, the HNF3 motif can be replaced by the HNF4
binding site from the TAT enhancer at -3.6 kb, and again
mutation of the latter results in loss of synergism with the
GRE in a promoter distal position. In contrast, neither HNF3
binding site tested in combination with the CRE was able to
confer liver-specific and cAMP-responsive stimulation of the
TK promoter (Fig. 4B). Whereas the HNF3 motifs were
functional in either orientation in combination with the GRE,
both HNF3 motifs (TAT-11 and TAT-2.5) when linked to the
CRE were inactive in either orientation (data not shown).
These results may indicate a strict requirement for a specific
alignment of the CRE and an adjacent binding site not met by
our constructs.
DISCUSSION
The work presented above has documented that the liver-
enriched transcription activators HNF3a, -13, and
-y and
HNF4 specifically interact with two hormone-responsive
enhancers of the TAT gene. While binding sites for these
transcription factors have been characterized in constitutive
regulatory sequences of other liver-specific genes (16, 23,
26-30), our results demonstrate that these elements in hor-
mone-responsive enhancers can function to restrict the ac-
tivity of ubiquitous signal transduction pathways to the liver.
In the TAT enhancer at -3.6 kb an HNF4 binding site
synergizes with the CRE to confer cAMP-inducible hepa-
toma cell-specific stimulation. HNF3 proteins bind in the
vicinity of the GRE in the glucocorticoid-inducible enhancer
at -2.5 kb, at a sequence motif which was previously
characterized as a second GRE (12, 31). Since the methyl-
ation interference pattern of the HNF3 protein-DNA com-
plexes correlates with the genomic footprint observed in
hepatoma cells (31), HNF3 proteins most likely interact in
vivo. Which of the three HNF3 proteins cooperates in vivo,
or whether they form a redundant system, has to remain an
open question until gene knockout experiments have been
performed. The regulatory properties of the enhancer can be
reconstituted by juxtaposing the HNF3 binding site and the
GRE. In vivo, it is likely that liver-enriched factors of the
C/EBP family also participate in determining the strong
glucocorticoid response in the liver (32, 33). The recently
postulated liver-enriched protein HNF5 (32, 33) is probably
identical with HNF3, since the HNF3 binding site that we
have identified coincides with one of the two putative HNF5
motifs described in the TAT enhancer at -2.5 kb and displays
a methylation interference pattern identical with that pub-
lished for HNF5. Moreover, the second postulated HNF5
binding site also interacts with HNF3 proteins (data not
shown).
In some systems, including the tryptophan oxygenase gene
and the mouse mammary tumor virus long terminal repeat,
sequence elements for ubiquitous factors adjacent to a GRE
have been documented to be important for hormone-
dependent stimulation (34-38). Transfection experiments
suggest that the presence of steroid hormone receptors is
sufficient to allow a transcriptional response upon adminis-
tration of the respective hormone (e.g., Fig. 4A). We have
shown here that a tissue-specific response can be elicited
through ubiquitous signaling pathways by coupling the target
A
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sequence (hormone response element) to binding sites for cell
type-specific transcription factors. The interdependence of
two or more essential transcriptional control elements per-
mits a finely tuned response also to small differences in factor
or hormone concentrations (39). Whereas a single GRE is
functional in close proximity to the transcription start site,
cooperation with a second GRE or another transcription
factor binding site is required for activation from a promoter-
distal position (Fig. 4A; ref. 19). As shown in Fig. 4B and by
the mutational analysis of the cAMP-responsive enhancer
(13), a CRE alone is not capable of eliciting acAMP response.
Thus, the upstream location combined with the modular
organization of the two hormone-inducible enhancers of the
TAT gene determines the tissue-specificity of the response.
The results presented in this study ascribe an important
role to HNF3 and HNF4 proteins in determining liver-
specific and hormone-inducible TAT gene activity. Expres-
sion of HNF3a, -,B, and -y and HNF4 is activated early in
liver cell differentiation and remains unchanged in the peri-
natal period (P. Monaghan and G.S., unpublished work).
Since the TAT gene is switched on only shortly after birth,
concomitant with changes in hormone concentrations, these
findings also indicate a role of signal transduction pathways
in the developmental activation of the gene. At birth, insulin
concentrations decrease whereas glucagon/cAMP and glu-
cocorticoid levels rise (40). The increase in intracellular
cAMP levels, a response to the neonatal hypoglycemia,
affects the binding ofand trans-activation by the CRE binding
protein CREB (21, 41, 42) thereby counteracting the inhibi-
tory effect of insulin on CRE function (R. Ganss, F. Weih,
and G.S., unpublished work). We propose that the synergism
between constitutive liver-specific control sequences and
targets of hormonal signal transduction pathways determines
the correct developmental activation of the TAT gene in the
liver.
We thank V. Prezioso, F. Sladek, and J. Darnell for gifts ofantisera
directed against HNF3 and HNF4. M. Nichols is gratefully acknowl-
edged for generously providing liver fractions. We thank R. Ganss,
G. Kelsey, A. Reik, and W. Schmid for critical reading of the
manuscript and W. Fleischer for oligonucleotide syntheses as well as
photographic work. This work was supported by the Deutsche
Forschungsgemeinschaft through Grant SFB 229, the Leibniz-
Programm, and Fonds der Chemischen Industrie.
1. Maniatis, T., Goodbourn, S. & Fischer, J. A. (1987) Science
236, 1237-1245.
2. Johnson, P. F. & McKnight, S. L. (1989) Annu. Rev. Biochem.
58, 799-839.
3. Green, S. & Chambon, P. (1988) Trends Genet. 4, 309-314.
4. Beato, M. (1989) Cell 56, 332-344.
5. Karin, M. & Smeal, T. (1992) Trends Biochem. Sci. 17, 418-
422.
6. Granner, D. K. & Beale, E. G. (1985) in Biochemical Actions
ofHormones, ed. Litwak, G. (Academic, New York), Vol. 12,
pp. 89-138.
7. Hashimoto, S., Schmid, W. & Schutz, G. (1984) Proc. Natl.
Acad. Sci. USA 81, 6637-6641.
8. Schmid, E., Schmid, W., Mayer, D., Jastorff, B. & Schutz, G.
(1987) Eur. J. Biochem. 165, 499-506.
9. Schubart, U. K. (1986) Endocrinology 119, 1741-1749.
10. Greengard, 0. (1970) in Mechanisms ofHormone Action, ed.
Litwack, G. (Academic, New York), Vol. 1, pp. 53-85.
11. Hargrove, J. L. & Granner, D. K. (1985) in Transaminases,
eds. Christen, P. & Metzler, P. E. (Wiley, New York), pp.
511-532.
12. Jantzen, H.-M., Strahle, U., Gloss, B., Stewart, F., Schmid,
W., Boshart, M., Miksicek, R. & Schutz, G. (1987) Cell 49,
29-38.
13. Boshart, M., Weih, F., Schmidt, A., Fournier, R. E. K. &
Schutz, G. (1990) Cell 61, 905-916.
14. Lai, E., Prezioso, V. R., Smith, E., Litvin, O., Costa, R. H. &
Damell, J. E., Jr. (1990) Genes Dev. 4, 1427-1436.
15. Lai, E., Prezioso, V. R., Tao, W., Chen, W. S. & Damell,
J. E., Jr. (1991) Genes Dev. 5, 416-427.
16. Sladek, F. M., Zhong, W., Lai, E. & Darnell, J. E., Jr. (1990)
Genes Dev. 4, 2353-2365.
17. Luckow, B. & Schutz, G. (1987) Nucleic Acids Res. 16, 5490.
18. Nitsch, D., Boshart, M. & Schutz, G. (1993) Genes Dev. 7,
308-319.
19. Strahle, U., Schmid, W. & Schutz, G. (1988) EMBO J. 7,
3389-3395.
20. Chen, E. Y. & Seeburg, P. H. (1985) DNA 4, 165-170.
21. Nichols, M., Weih, F., Schmid, W., DeVack, C., Kowenz-
Leutz, E., Luckow, B., Boshart, M. & Schutz, G. (1992)
EMBO J. 11, 3337-3346.
22. Nitsch, D., Stewart, A. F., Boshart, M., Mestril, R., Weih, F.
& Schutz, G. (1990) Mol. Cell. Biol. 10, 3334-3342.
23. Costa, R. H., Grayson, D. R. & Darnell, J. E. (1989) Mol. Cell.
Biol. 9, 1415-1425.
24. Weigel, D. & Jackle, H. (1990) Cell 63, 455-456.
25. Tao, W. & Lai, E. (1992) Neuron 8, 957-966.
26. Ladias, J. A. A., Hadzopoulou-Cladaras, M., Kardassis, D.,
Cardot, P., Cheng, J., Zannis, V. & Cladaras, C. (1992) J. Biol.
Chem. 267, 15849-15860.
27. Ip, Y. T., Poon, D., Stone, D., Granner, D. K. & Chakley, R.
(1990) Mol. Cell. Biol. 10, 3770-3781.
28. DiPersio, C. M., Jackson, D. A. & Zaret, K. S. (1991) Mol.
Cell. Biol. 9, 4405-4414.
29. Brooks, A. R., Blackhart, B. D., Haubold, K. & Levy-Wilson,
B. (1991) J. Biol. Chem. 266, 7848-7859.
30. Mietus-Snyder, M., Sladek, F. M., Ginsburg, G. S., Kuo,
C. F., Ladias, J. A. A., Darnell, J. E., Jr., & Karathanasis,
S. K. (1992) Mol. Cell. Biol. 12, 1708-1718.
31. Becker, P., Gloss, B., Schmid, W., Strahle, U. & Schutz, G.
(1986) Nature (London) 324, 686-688.
32. Grange, T., Roux, J., Rigaud, G. & Pictet, R. (1991) Nucleic
Acids Res. 19, 131-139.
33. Rigaud, G., Roux, J., Pictet, R. & Grange, T. (1991) Cell 67,
977-986.
34. Buetti, E. & Diggelmann, H. (1986) J. Mol. Biol. 190, 379-389.
35. Miksicek, R., Heber, A., Schmid, W., Danesch, U., Posseck-
ert, G., Beato, M. & Schutz, G. (1986) Cell 46, 283-290.
36. Danesch, U., Gloss, B., Schmid, W., Schutz, G. & Renkawitz,
R. (1987) EMBO J. 6, 625-630.
37. Pifia, B., Bruggemeier, U. & Beato, M. (1990) Cell 60, 719-731.
38. Bruggemeier, U., Kalif, M., Franke, S., Scheidereit, C. &
Beato, M. (1991) Cell 64, 565-572.
39. Falvey, E. & Schibler, U. (1991) FASEB J. 5, 309-314.
40. McGrane, M. M., Yun, J. S., Patel, Y. M. & Hanson, R. W.
(1992) Trends Biochem. Sci. 17, 40-44.
41. Gonzalez, G. A. & Montminy, M. R. (1989) Cell 59, 145-157.
42. Weih, F., Stewart, A. F., Boshart, M., Nitsch, D. & Schutz, G.
(1990) Genes Dev. 4, 1437-1449.
Genetics: Nitsch et al.
